Does Granulocyte Colony-Stimulating Factor Worsen Anemia in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?
Paola Papaldo(Cancer Institute (WIA)), Francesco Cognetti(Apple (Israel)), Claudio Botti(Catholic University of America), Giuseppe Naso(Policlinico Umberto I), Paolo Carlini(National Cancer Institute), Marcella Mottolese, E. Terzoli(Catholic University of America), Franco Di Filippo, Cecilia Nisticò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Enzo Maria Ruggeri, G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Mauro Antimi(Catholic University of America), Paolo Marolla(Catholic University of America), Diana Giannarelli(Agostino Gemelli University Polyclinic), Enrico Cortesi(Sapienza University of Rome), Luigi Di Lauro, Anna Ceribelli(St. Eugenio Hospital), Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), Massimo Lopez(Catholic University of America), Patrizia Vici(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 42
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k